Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 718

Results For "ENT"

9400 News Found

COVID is not over yet, says Union Health Minister
Policy | June 14, 2022

COVID is not over yet, says Union Health Minister

Increased and timely testing will enable early identification of COVID cases and help to curb spread of the infection among the community


Dr. Bharati Pravin Pawar launches Intensified Diarrhoea Control Fortnight – 2022
News | June 14, 2022

Dr. Bharati Pravin Pawar launches Intensified Diarrhoea Control Fortnight – 2022

The IDCF programme is being implemented from 13th June to 27th June, 2022 in the states/UTs and the goal is to attain zero child deaths due to childhood diarrhoea


Philips announces positive research results from its TOBA II BTK clinical trial
Clinical Trials | June 14, 2022

Philips announces positive research results from its TOBA II BTK clinical trial

First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization


Nuvectis announces positive data for NXP900 in a preclinical model of Group 4 medulloblastoma
News | June 14, 2022

Nuvectis announces positive data for NXP900 in a preclinical model of Group 4 medulloblastoma

Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease


Sanofi-GSK next-gen COVID-19 booster delivers strong immune response against main variants
News | June 14, 2022

Sanofi-GSK next-gen COVID-19 booster delivers strong immune response against main variants

Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile


FDA accepts application for Merck’s Keytruda as adjuvant therapy for Stage IB-IIIA lung cancer
Drug Approval | June 14, 2022

FDA accepts application for Merck’s Keytruda as adjuvant therapy for Stage IB-IIIA lung cancer

Acceptance based on results from the phase 3 KEYNOTE-091 trial


Quizartinib Plus chemotherapy significantly improved overall survival compared to chemo
News | June 12, 2022

Quizartinib Plus chemotherapy significantly improved overall survival compared to chemo

Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium


Amytrx Therapeutic's AMTX-100 CF3 moves to phase II clinical trial for atopic dermatitis
Clinical Trials | June 12, 2022

Amytrx Therapeutic's AMTX-100 CF3 moves to phase II clinical trial for atopic dermatitis

Amarex Clinical Research guides its client to phase II of FDA trials


Strides receives USFDA approval for Ibuprofen OTC oral suspension
Drug Approval | June 12, 2022

Strides receives USFDA approval for Ibuprofen OTC oral suspension

Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.


Isotopia and CPDC deliver first doses of n.c.a. Lu-177 to North American customers
News | June 12, 2022

Isotopia and CPDC deliver first doses of n.c.a. Lu-177 to North American customers

The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America